公开(公告)号：US08956647B2

公开(公告)日：2015-02-17

申请号：US13951951

申请日：2013-07-26

Applicant: Norbert Otterbeck ,  Peter Gruber

Inventor： Norbert Otterbeck ,  Peter Gruber

IPC: A61K9/52 ,  A61K9/00 ,  A61K9/16 ,  A61K9/50 ,  A61K31/60 ,  A61K9/14 ,  A61K31/606

CPC classification number: A61K9/0053 ,  A61K9/141 ,  A61K9/16 ,  A61K9/1635 ,  A61K9/1652 ,  A61K9/501 ,  A61K9/5026 ,  A61K9/5042 ,  A61K31/60 ,  A61K31/606

Abstract: An orally administrable pharmaceutical pellet formulation for the treatment of the intestinal tract is disclosed, which comprises a core and an enteric coating, the core including, as a pharmaceutical active compound, aminosalicylic acid or a pharmaceutically tolerable salt or a derivative thereof.

公开(公告)号：US5932249A

公开(公告)日：1999-08-03

申请号：US619556

申请日：1996-07-15

Applicant: Peter Gruber ,  Hans Joachim Lach ,  Norbert Otterbeck

Inventor： Peter Gruber ,  Hans Joachim Lach ,  Norbert Otterbeck

IPC: A61K9/28 ,  A61K9/50 ,  A61K9/52 ,  A61K9/54 ,  A61K31/58 ,  A61K47/32 ,  A61K9/14

CPC classification number: C12Y304/24 ,  A61K31/58 ,  A61K9/5078

Abstract: Disclosed are budesonide pellets with a controlled release pattern containing, from the inside to the outside: a) neutral pellets; b) an active principle layer of micronized budesonide and one or more water-soluble auxiliaries; c) a first lacquer coating consisting of 80 to 97% of at least one lacquer insoluble in gastric fluids but soluble in intestinal fluids and 3 to 20% of at least one lacquer insoluble in both gastric and intestinal fluids; and d) a second lacquer coating consisting of at least one lacquer insoluble in gastric and intestinal fluids. The invention also relates to a process for producing budesonide pellets with a controlled release pattern.

Abstract translation: PCT No.PCT / EP94 / 02531 Sec。 371日期：1996年7月15日 102（e）日期1996年7月15日PCT提交1994年7月29日PCT公布。 公开号WO95 / 08323 日期1995年3月30日公开是具有控制释放模式的布地奈德颗粒，其包含从内到外的：a）中性颗粒; b）微粉化布地奈德和一种或多种水溶性助剂的活性主层; c）第一漆包衣，其由80-97％的至少一种不溶于胃液但可溶于肠液的漆和3至20％至少一种不溶于胃液和肠液的漆组成; 和d）由至少一种不溶于胃液和肠液的漆组成的第二漆层。 本发明还涉及一种具有控制释放模式的布地奈德颗粒的制备方法。

公开(公告)号：US08911778B2

公开(公告)日：2014-12-16

申请号：US13566905

申请日：2012-08-03

Applicant: Norbert Otterbeck ,  Peter Gruber

Inventor： Norbert Otterbeck ,  Peter Gruber

IPC: A61K9/52 ,  A61K9/56 ,  A61K9/60 ,  A61K9/50 ,  A61K9/16 ,  A61K9/14 ,  A61K31/60 ,  A61K31/606 ,  A61K9/00

CPC classification number: A61K9/0053 ,  A61K9/141 ,  A61K9/16 ,  A61K9/1635 ,  A61K9/1652 ,  A61K9/501 ,  A61K9/5026 ,  A61K9/5042 ,  A61K31/60 ,  A61K31/606

Abstract: An orally adminsterable pharmaceutical pellet formulation for the treatment of the intestinal tract is disclosed, which comprises a core and an enteric coating, the core including, as a pharmaceutical active compound, aminosalicylic acid or a pharmaceutically tolerable salt or a derivative thereof.

Abstract translation: 公开了一种用于治疗肠道的口服可用药物丸剂制剂，其包含核心和肠溶衣，核心包括作为药物活性化合物的氨基水杨酸或其药学上可耐受的盐或其衍生物。

公开(公告)号：US07547451B2

公开(公告)日：2009-06-16

申请号：US10360410

申请日：2003-02-07

Applicant: Norbert Otterbeck

Inventor： Norbert Otterbeck

IPC: A61K9/52 ,  A61K9/28

CPC classification number: A61K9/0053 ,  A61K9/141 ,  A61K9/16 ,  A61K9/1635 ,  A61K9/1652 ,  A61K9/501 ,  A61K9/5026 ,  A61K9/5042 ,  A61K31/60 ,  A61K31/606

Abstract: An orally adminsterable pharmaceutical pellet formulation for the treatment of the intestinal tract is disclosed, which comprises a core and an enteric coating, the core including, as a pharmaceutical active compound, aminosalicylic acid or a pharmaceutically tolerable salt or a derivative thereof.

Abstract translation: 公开了一种用于治疗肠道的口服可用药物丸剂制剂，其包含核心和肠溶衣，核心包括作为药物活性化合物的氨基水杨酸或其药学上可耐受的盐或其衍生物。

公开(公告)号：US06551620B2

公开(公告)日：2003-04-22

申请号：US09906494

申请日：2001-07-16

Applicant: Norbert Otterbeck

Inventor： Norbert Otterbeck

IPC: A61K3160

CPC classification number: A61K9/0053 ,  A61K9/141 ,  A61K9/16 ,  A61K9/1635 ,  A61K9/1652 ,  A61K9/501 ,  A61K9/5026 ,  A61K9/5042 ,  A61K31/60 ,  A61K31/606

Abstract: An orally adminsterable pharmaceutical pellet formulation for the treatment of the intestinal tract is disclosed, which comprises a core and an enteric coating, the core including, as a pharmaceutical active compound, aminosalicylic acid or a pharmaceutically tolerable salt or a derivative thereof.

公开(公告)号：US08496965B2

公开(公告)日：2013-07-30

申请号：US13586585

申请日：2012-08-15

Applicant: Norbert Otterbeck

Inventor： Norbert Otterbeck

IPC: A61K9/28

CPC classification number: A61K9/0053 ,  A61K9/141 ,  A61K9/16 ,  A61K9/1635 ,  A61K9/1652 ,  A61K9/501 ,  A61K9/5026 ,  A61K9/5042 ,  A61K31/60 ,  A61K31/606

Abstract: An orally adminsterable pharmaceutical pellet formulation for the treatment of the intestinal tract is disclosed, which comprises a core and an enteric coating, the core including, as a pharmaceutical active compound, aminosalicylic acid or a pharmaceutically tolerable salt or a derivative thereof.

公开(公告)号：US20090017117A1

公开(公告)日：2009-01-15

申请号：US12236157

申请日：2008-09-23

Applicant: Norbert Otterbeck

Inventor： Norbert Otterbeck

IPC: A61K9/26 ,  A61K31/606 ,  A61K31/625 ,  A61K31/655

CPC classification number: A61K9/0053 ,  A61K9/141 ,  A61K9/16 ,  A61K9/1635 ,  A61K9/1652 ,  A61K9/501 ,  A61K9/5026 ,  A61K9/5042 ,  A61K31/60 ,  A61K31/606

Abstract: An orally adminsterable pharmaceutical pellet formulation for the treatment of the intestinal tract is disclosed, which comprises a core and an enteric coating, the core including, as a pharmaceutical active compound, aminosalicylic acid or a pharmaceutically tolerable salt or a derivative thereof.

Abstract translation: 公开了一种用于治疗肠道的口服可用药物丸剂制剂，其包含核心和肠溶衣，核心包括作为药物活性化合物的氨基水杨酸或其药学上可耐受的盐或其衍生物。

公开(公告)号：US5914122A

公开(公告)日：1999-06-22

申请号：US860136

申请日：1997-06-27

Applicant: Norbert Otterbeck ,  Reimund Kuhn

Inventor： Norbert Otterbeck ,  Reimund Kuhn

IPC: A61K9/08 ,  A61K9/00 ,  A61K9/12 ,  A61K31/575 ,  A61K31/58 ,  A61K47/02 ,  A61K47/10 ,  A61K47/18 ,  A61K47/40 ,  A61F2/02

CPC classification number: A61K31/58 ,  A61K9/0031

Abstract: A stable budesonide solution with a pH not exceeding 6.0 in which the budesonide is dissolved in a solvent which may be water, an alcohol such as ethanol, isopropanol or propylene glycol, or a water/alcohol mixture. The solution preferably also contains a stabilizer such as sodium ethylenediaminetetraacetic acid, cyclodextrins or mixtures thereof. The stable budesonide solution is useful as the active ingredient in a rectal enema or a rectal foam.

Abstract translation: 不超过6.0的布地奈德的稳定布地奈德溶液，其中布地奈德溶解在可以是水，醇如乙醇，异丙醇或丙二醇的醇或水/醇混合物的溶剂中。 该溶液优选还含有稳定剂如乙二胺四乙酸钠，环糊精或其混合物。 稳定的布地奈德溶液可用作直肠灌肠剂或直肠泡沫中的活性成分。

公开(公告)号：US08337886B2

公开(公告)日：2012-12-25

申请号：US12236157

申请日：2008-09-23

Applicant: Norbert Otterbeck

Inventor： Norbert Otterbeck

IPC: A61K9/28 ,  A61K9/52

CPC classification number: A61K9/0053 ,  A61K9/141 ,  A61K9/16 ,  A61K9/1635 ,  A61K9/1652 ,  A61K9/501 ,  A61K9/5026 ,  A61K9/5042 ,  A61K31/60 ,  A61K31/606

Abstract: An orally adminsterable pharmaceutical pellet formulation for the treatment of the intestinal tract is disclosed, which comprises a core and an enteric coating, the core including, as a pharmaceutical active compound, aminosalicylic acid or a pharmaceutically tolerable salt or a derivative thereof.

Abstract translation: 公开了一种用于治疗肠道的口服可用药物丸剂制剂，其包含核心和肠溶衣，核心包括作为药物活性化合物的氨基水杨酸或其药学上可耐受的盐或其衍生物。

公开(公告)号：US20130189356A1

公开(公告)日：2013-07-25

申请号：US13790809

申请日：2013-03-08

Applicant: Norbert Otterbeck

Inventor： Norbert Otterbeck

IPC: A61K9/14

CPC classification number: A61K9/0053 ,  A61K9/141 ,  A61K9/16 ,  A61K9/1635 ,  A61K9/1652 ,  A61K9/501 ,  A61K9/5026 ,  A61K9/5042 ,  A61K31/60 ,  A61K31/606

Abstract: An orally administrable pharmaceutical pellet formulation for the treatment of the intestinal tract is disclosed, which comprises a core and an enteric coating, the core including, as a pharmaceutical active compound, aminosalicylic acid or a pharmaceutically tolerable salt or a derivative thereof.